Unknown

Dataset Information

0

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.


ABSTRACT: Purpose: Vitamin D exerts its inhibitory influence on colon cancer growth by inhibiting Wnt signaling and angiogenesis. We hypothesized that SNPs in genes involved in vitamin D transport, metabolism, and signaling are associated with outcome in metastatic colorectal cancer (mCRC) patients treated with first-line FOLFIRI and bevacizumab.Experimental Design: 522 mCRC patients enrolled in the FIRE-3 (discovery cohort) and TRIBE (validation set) trials treated with FOLFIRI/bevacizumab were included in this study. 278 patients receiving FOLFIRI and cetuximab (FIRE-3) served as a control cohort. Six SNPs in 6 genes (GC, CYP24A1, CYP27B1, VDR, DKK1, CST5) were analyzed.Results: In the discovery cohort, AA carriers of the GC rs4588 SNP encoding for the vitamin D-binding protein, and treated with FOLFIRI/bevacizumab had a shorter overall survival (OS) than those harboring any C allele (15.9 vs. 25.1 months) in both univariable (P = 0.001) and multivariable analyses (P = 0.047). This association was confirmed in the validation cohort in multivariable analysis (OS 18.1 vs. 26.2 months, HR, 1.83; P = 0.037). Interestingly, AA carriers in the control set exhibited a longer OS (48.0 vs. 25.2 months, HR, 0.50; P = 0.021). This association was further confirmed in a second validation cohort comprising refractory mCRC patients treated with cetuximab ± irinotecan (PFS 8.7 vs. 3.7 months) in univariable (P = 0.033) and multivariable analyses (P = 0.046).Conclusions:GC rs4588 SNP might serve as a predictive marker in mCRC patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab. Whereas AA carriers derive a survival benefit with FOLFIRI/cetuximab, treatment with FOLFIRI/bevacizumab is associated with a worse outcome. Clin Cancer Res; 24(4); 784-93. ©2017 AACR.

SUBMITTER: Berger MD 

PROVIDER: S-EPMC7505162 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.

Berger Martin D MD   Stintzing Sebastian S   Heinemann Volker V   Cao Shu S   Yang Dongyun D   Sunakawa Yu Y   Matsusaka Satoshi S   Ning Yan Y   Okazaki Satoshi S   Miyamoto Yuji Y   Suenaga Mitsukuni M   Schirripa Marta M   Hanna Diana L DL   Soni Shivani S   Puccini Alberto A   Zhang Wu W   Cremolini Chiara C   Falcone Alfredo A   Loupakis Fotios F   Lenz Heinz-Josef HJ  

Clinical cancer research : an official journal of the American Association for Cancer Research 20171205 4


<b>Purpose:</b> Vitamin D exerts its inhibitory influence on colon cancer growth by inhibiting Wnt signaling and angiogenesis. We hypothesized that SNPs in genes involved in vitamin D transport, metabolism, and signaling are associated with outcome in metastatic colorectal cancer (mCRC) patients treated with first-line FOLFIRI and bevacizumab.<b>Experimental Design:</b> 522 mCRC patients enrolled in the FIRE-3 (discovery cohort) and TRIBE (validation set) trials treated with FOLFIRI/bevacizumab  ...[more]

Similar Datasets

| S-EPMC7513926 | biostudies-literature
| S-EPMC4936942 | biostudies-literature
| S-EPMC4155520 | biostudies-literature
| S-EPMC7496215 | biostudies-literature
| S-EPMC6342906 | biostudies-literature
| S-EPMC3528380 | biostudies-literature
| S-EPMC5471055 | biostudies-literature
| S-EPMC9427779 | biostudies-literature
| S-EPMC6700318 | biostudies-literature
| S-EPMC4532210 | biostudies-literature